U.S. agency slaps down a J&J plan to switch payments for 340B hospitals

Taking stock of the drug industry, from the lab to the medicine chest

August 23, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Mario Tama/Getty Images STAT+ | U.S. agency slaps down a J&J plan to switch payments for 340B hospitals "This move (by Johnson & Johnson) undermines the very foundation of the 340B program," said Maureen Testoni of 340B Health. By Ed Silverman STAT+ | Settlement blocks diagnostics maker EpicGenetics from selling two questionable blood tests EpicGenetics will discontinue a test it said could definitively diagnose fibromyalgia as part of the settlement with consumer watchdog CSPI. By Eric Boodman Takeaways from the DNC on the health care fights ahead The convention showed the health issues Harris and Walz care most about. The Republican counterattacks are already starting. By Sarah Owermohle Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman STAT+ | AI in medicine: A national registry could help increase transparency, experts say A national registry for artificial intelligence systems used in health care could help increase transparency, and eventually improve safety. By Casey Ross

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser